147 related articles for article (PubMed ID: 7734313)
1. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
Pera MF; Köberle B; Masters JR
Br J Cancer; 1995 May; 71(5):904-6. PubMed ID: 7734313
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors.
Varuni Kondagunta G; Bacik J; Schwartz L; Sheinfeld J; Bajorin D; Vuky J; Marion S; Mazumdar M; Bosl GJ; Motzer RJ
Invest New Drugs; 2004 Apr; 22(2):177-9. PubMed ID: 14739666
[TBL] [Abstract][Full Text] [Related]
3. Genetic basis of drug sensitivity in human testis tumour cells.
Wang X; Hafezparast M; Masters JR
Int J Cancer; 1996 Feb; 65(4):426-31. PubMed ID: 8621221
[TBL] [Abstract][Full Text] [Related]
4. Role of metallothionein in cisplatin sensitivity of germ-cell tumours.
Meijer C; Timmer A; De Vries EG; Groten JP; Knol A; Zwart N; Dam WA; Sleijfer DT; Mulder NH
Int J Cancer; 2000 Mar; 85(6):777-81. PubMed ID: 10709094
[TBL] [Abstract][Full Text] [Related]
5. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines.
Dunn TA; Schmoll HJ; Grünwald V; Bokemeyer C; Casper J
Invest New Drugs; 1997; 15(2):109-14. PubMed ID: 9220289
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
Fosså SD; Stenning SP; Gerl A; Horwich A; Clark PI; Wilkinson PM; Jones WG; Williams MV; Oliver RT; Newlands ES; Mead GM; Cullen MH; Kaye SB; Rustin GJ; Cook PA
Br J Cancer; 1999 Jul; 80(9):1392-9. PubMed ID: 10424741
[TBL] [Abstract][Full Text] [Related]
7. Brief report: phase II multicenter study of temozolomide in patients with cisplatin-resistant germ cell tumors.
Maroto P; Huddart R; Garcia del Muro X; Horwich A; Paz Ares L; Aparicio J; Germa-Lluch JR
Oncology; 2011; 80(3-4):219-22. PubMed ID: 21734411
[TBL] [Abstract][Full Text] [Related]
8. DNA repair capacity and cisplatin sensitivity of human testis tumour cells.
Köberle B; Grimaldi KA; Sunters A; Hartley JA; Kelland LR; Masters JR
Int J Cancer; 1997 Mar; 70(5):551-5. PubMed ID: 9052754
[TBL] [Abstract][Full Text] [Related]
9. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
Bokemeyer C
Oncology; 1998; 55(3):177-88. PubMed ID: 9560052
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways.
Masters JR; Thomas R; Hall AG; Hogarth L; Matheson EC; Cattan AR; Lohrer H
Eur J Cancer; 1996 Jun; 32A(7):1248-53. PubMed ID: 8758261
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vivo and in vitro.
Harstrick A; Casper J; Guba R; Wilke H; Poliwoda H; Schmoll HJ
Cancer; 1989 Mar; 63(6):1079-83. PubMed ID: 2645036
[TBL] [Abstract][Full Text] [Related]
12. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
13. Human germ cell tumours: expression of gamma-glutamyl transpeptidase and sensitivity to cisplatin.
Hanigan MH; Frierson HF; Abeler VM; Kaern J; Taylor PT
Br J Cancer; 1999 Sep; 81(1):75-9. PubMed ID: 10487615
[TBL] [Abstract][Full Text] [Related]
14. Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenografts.
Dunn TA; Grünwald V; Bokemeyer C; Casper J
Invest New Drugs; 1997; 15(2):91-8. PubMed ID: 9220287
[TBL] [Abstract][Full Text] [Related]
15. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
[TBL] [Abstract][Full Text] [Related]
16. In vitro drug sensitivity testing of human testicular germ cell tumours with cytostatic drugs and interferon alpha-2b.
Küpeli B; Baltaci S; Beksac M; Süzer O; Küpeli S; Göğüs O
Int Urol Nephrol; 1997; 29(1):79-84. PubMed ID: 9203042
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of cisplatin-resistant human testicular and bladder tumour cell lines.
Walker MC; Povey S; Parrington JM; Riddle PN; Knuechel R; Masters JR
Eur J Cancer; 1990; 26(6):742-7. PubMed ID: 2144165
[TBL] [Abstract][Full Text] [Related]
18. Screening of new anticancer agents in vitro using panels of human cell lines derived from non-seminomatous germ cell tumours and transitional cell carcinomas of the bladder.
Masters JR; Jenkins WE; Shoemaker RH
Eur J Cancer; 1992; 28A(10):1617-22. PubMed ID: 1389475
[TBL] [Abstract][Full Text] [Related]
19. Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience.
Gerl A; Clemm C; Schmeller N; Hartenstein R; Lamerz R; Wilmanns W
Br J Cancer; 1996 Oct; 74(8):1280-5. PubMed ID: 8883418
[TBL] [Abstract][Full Text] [Related]
20. DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction.
Köberle B; Payne J; Grimaldi KA; Hartley JA; Masters JR
Biochem Pharmacol; 1996 Dec; 52(11):1729-34. PubMed ID: 8986135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
